Certara, Inc. (NASDAQ:CERT) Shares Sold by Nicolet Advisory Services LLC

Nicolet Advisory Services LLC reduced its position in Certara, Inc. (NASDAQ:CERT) by 39.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 14,956 shares of the company’s stock after selling 9,875 shares during the quarter. Nicolet Advisory Services LLC’s holdings in Certara were worth $159,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. raised its position in shares of Certara by 1.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 699,575 shares of the company’s stock valued at $8,192,000 after buying an additional 12,720 shares during the last quarter. State Street Corp lifted its stake in Certara by 3.4% in the 3rd quarter. State Street Corp now owns 3,679,699 shares of the company’s stock worth $43,089,000 after purchasing an additional 122,411 shares in the last quarter. Jane Street Group LLC boosted its holdings in shares of Certara by 2.6% during the 3rd quarter. Jane Street Group LLC now owns 147,393 shares of the company’s stock worth $1,726,000 after purchasing an additional 3,732 shares during the last quarter. Barclays PLC grew its position in shares of Certara by 198.3% in the third quarter. Barclays PLC now owns 70,525 shares of the company’s stock valued at $825,000 after purchasing an additional 46,880 shares in the last quarter. Finally, 272 Capital LP acquired a new stake in shares of Certara in the third quarter valued at approximately $586,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Analysts Set New Price Targets

CERT has been the subject of several analyst reports. Barclays upped their target price on Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. Stephens reissued an “overweight” rating and issued a $17.00 price objective on shares of Certara in a report on Thursday, February 27th. TD Cowen initiated coverage on shares of Certara in a research note on Thursday, February 27th. They set a “buy” rating and a $16.00 target price on the stock. Finally, William Blair reissued a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $15.83.

Certara Price Performance

Shares of CERT opened at $9.55 on Friday. The firm has a 50-day simple moving average of $12.14 and a two-hundred day simple moving average of $11.41. The stock has a market cap of $1.54 billion, a PE ratio of -47.75, a P/E/G ratio of 9.29 and a beta of 1.64. Certara, Inc. has a 1-year low of $9.21 and a 1-year high of $19.18. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.